Business Context and Reporting Period
This Form 8-K Current Report was filed by Neuralstem, Inc. on August 9, 2018, covering events occurring on August 4, 2018, and August 6, 2018. The filing primarily addresses the appointment of new interim leadership and the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and corporate governance changes.
Material Changes
The material change reported is the appointment of Jim Scully as Interim Chief Executive Officer and Principal Accounting Officer, effective August 1, 2018. Key terms of the binding term sheet executed on August 4, 2018, include:
- Compensation: $25,000 per calendar month for three full days of work per week, with an additional $2,000 per day for extra service.
- Term: Six months, ending January 31, 2019, subject to 60 days prior notice for termination.
- Equity Grant: An option to purchase 250,000 shares of common stock at an exercise price of $1.15 per share.
- Vesting and Clawback: The option is fully vested on the grant date but includes a clawback provision requiring repayment of gains or share repurchase if Mr. Scully voluntarily leaves or is terminated for cause before completing the term.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business operations. The primary risk disclosed relates to the equity compensation structure, specifically the requirement for Mr. Scully to complete the full six-month term to retain the economic benefit of the stock option grant without penalty.
Investor Verification Checklist
- Verify the exact end date of the interim term (noted as January 31, 2018 in the text, likely a typo for 2019 given the August 2018 start date).
- Review the attached Exhibit 10.01 (Binding Term Sheet) for complete legal terms regarding the stock option clawback provisions.
- Confirm the total number of shares outstanding post-grant to assess dilution impact of the 250,000 share option.
- Check subsequent filings for the execution of the formal employment agreement mentioned as anticipated.